Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1532-1537

  Zinzani, Pier Luigi ^a   Pileri, Stefano ^a   Bendandi, Maurizio ^a   Buzzi, Marina ^a   Sabattini, Elena ^a   Ascani, Stefano ^a   Gherlinzoni, Filippo ^a   Magagnoli, Massimo ^a   Albertini, Patrizia ^a   Tura, Sante ^a  

^a Institute of Hematology and Oncology Seràgnoli   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031900563     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1532     Document Type: Article

References (29)

1. Schwarting R, Gerdes J, Durkop H, et al: Ber-H2: A new anti Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 74:1678-1689, 1989
2. Falini B, Pileri S, Pizzolo G, et al: CD 30 (Ki-1) molecule: A new cytokine receptor of the TNF receptor superfamily as a target for diagnosis and immunotherapy. Blood 85:1-14, 1995
3. Stein H, Herbst H, Anagnostopoulos I, et al: The nature of Hodgkin and Reed-Sternberg cells, their association with EBV, and their relationship to anaplastic large-cell lymphoma. Ann Oncol 2:33-38, 1991
4. Stein H, Gerdes J, Tippelmann G, et al: Ki-1 lymphoma experimental and clinical findings. Third International Conference on Malignant Lymphoma. Lugano, Switzerland, June 10-13, 1987
5. Pileri S, Falini B, Delsol G, et al: Lymphohistiocytic T-cell lymphoma (anaplastic large-cell lymphoma CD30+/Ki-1+ with a high content of reactive histiocytes). Histopathol 16:383-391, 1990
6. Pileri S, Sabattini E, Poggi S, Amini M, Falini B, Stein H. Lymphohistiocytic T-cell lymphoma. Histopathology 25:191-193, 1994
7. Harris NL, Jaffe ES, Stein H, et al: A proposal for an international consensus on the classification of lymphoid neoplasms. Blood 84:1361-1392, 1994
8. Blay JY, Burdin N, Rousset Lenoir G, et al: Serum interleukin-10 in non-Hodgkin's lymphoma: A prognostic factor. Blood 82:2169-2174, 1993
9. Stasi R, Zinzani PL, Galieni P, et al: Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol 88:770-777, 1994
10. Stasi R, Zinzani PL, Galieni P, et al: Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Cancer 74:1792-1800, 1994
11. Stasi R, Zinzani PL, Galieni P, et al: Clinical implications of cytokine and soluble receptor measurements in patients with newly diagnosed aggressive non-Hodgkin's lymphoma. Eur J Haematol 54:9-17, 1995
12. Pizzolo G, Vinante F, Chilosi M, et al: Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: Relationship with disease activity and clinical stage. Br J Haematol 75:282-284, 1990
13. Gause A, Pohl C, Tschiersch A, et al: Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood. 77:1983-1988, 1991
14. Nadali G, Vinante F, Ambrosetti A, et al: Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 12:793-797, 1994
15. Nadali G, Vinante F, Stein H, et al: Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. J Clin Oncol 13:1355-1360, 1995
16. Guglielmi C, Amadori S, Anselmo AP, et al: Sequential combination chemotherapy of high-grade non-Hodgkin's lymphoma with 5-fluorouracil, methotrexate, cytosine-arabinoside, cyclophosphamide, doxorubicin, vincristine and prednisone (F-MACHOP). Cancer Invest 5:159-169, 1987
17. Klimo P, Connors JM: MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596-602, 1985
18. Paulli M, Berti E, Rosso R, et al: CD30/Ki-1-positive lymphoproliferative disorders of the skin. Clinicopathologic correlation and statistical analysis of 86 cases: A multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol 13:1343-1354, 1995
19. Carbone PP, Kaplan HS, Musshoff K, et al: Report of the committee on Hodgkin's disease staging classification. Cancer Res 31:1860-1861, 1971
20. Oken M, Creech R, Tormey D: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
21. Zinzani PL, Bendandi M, Martelli M, et al: Anaplastic large-cell lymphoma: Clinical and prognostic evaluation of 90 adult patients. J Clin Oncol 14:955-962, 1996
22. Kaplan EL, Meyer P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Cox DR: Analysis of Binary Data. London, UK. Metheun, 1970
24. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
25. The International non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
26. Stein H, Mason DY, Gerdes J, et al: The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cell. Blood 66:848-858, 1985
27. Smith CA, Gruss HJ, Davis T, et al: CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73:1349-1353, 1993
28. Josimovic-Alasevic O, Durkop H, Schwarting R, et al: Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 19:157-162, 1989
29. Pileri S, Bocchia M, Baroni CD, et al: Anaplastic large-cell lymphoma (CD30+/KM-1+): Results of a prospective clinicopathological study of 69 cases. Br J Haematol 86:513-523, 1994